{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T20:27:44Z","timestamp":1680726464333},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tech Coloproctol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s10151-016-1477-8","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T10:10:19Z","timestamp":1463134219000},"page":"433-436","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prucalopride: For functional constipation only?"],"prefix":"10.1007","volume":"20","author":[{"given":"M.","family":"Bellini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Gambaccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Bassotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"1477_CR1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/apt.12571","volume":"39","author":"A Shin","year":"2014","unstructured":"Shin A, Camilleri M, Kolar G, Erwin P, West CP, Murad MH (2014) Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 39:239\u2013253","journal-title":"Aliment Pharmacol Ther"},{"key":"1477_CR2","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/nm0912-1308","volume":"18","author":"E Dolgin","year":"2012","unstructured":"Dolgin E (2012) Drug pipeline is flush with new options for chronic constipation. Nat Med 18:1308\u20131309","journal-title":"Nat Med"},{"key":"1477_CR3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1586\/17474124.2016.1129897","volume":"10","author":"G Bassotti","year":"2016","unstructured":"Bassotti G, Gambaccini D, Bellini M (2016) Prucalopride succinate for the treatment of chronic constipation: an update and future directions. Expert Rev Gastroenterol Hepatol 10:291\u2013300","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1477_CR4","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/sj.bjp.0703985","volume":"132","author":"NH Prins","year":"2001","unstructured":"Prins NH, van Der Grijn A, Lefebvre RA, Akkermans LM, Schuurkes JA (2001) 5-HT(4) receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study. Br J Pharmacol 132:1941\u20131947","journal-title":"Br J Pharmacol"},{"key":"1477_CR5","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjp.0704376","volume":"134","author":"NH Prins","year":"2001","unstructured":"Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA (2001) Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle. Br J Pharmacol 134:1351\u20131359","journal-title":"Br J Pharmacol"},{"key":"1477_CR6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.bjp.0704471","volume":"135","author":"PG Leclere","year":"2002","unstructured":"Leclere PG, Lefebvre RA (2002) Presynaptic modulation of cholinergic neurotransmission in the human proximal stomach. Br J Pharmacol 135:135\u2013142","journal-title":"Br J Pharmacol"},{"key":"1477_CR7","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/nmo.12394","volume":"26","author":"J Broad","year":"2014","unstructured":"Broad J, Hughes F, Chin-Aleong J, Sifrim D, Sanger GJ (2014) Regionally dependent neuromuscular functions of motilin and 5-HT4 receptors in human isolated esophageal body and gastric fundus. Neurogastroenterol Motil 26:1311\u20131322","journal-title":"Neurogastroenterol Motil"},{"key":"1477_CR8","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/nmo.12359","volume":"26","author":"BF Kessing","year":"2014","unstructured":"Kessing BF, Smout AJ, Bennink RJ, Kraaijpoel N, Oors JM, Bredenoord AJ (2014) Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neurogastroenterol Motil 26:1079\u20131086","journal-title":"Neurogastroenterol Motil"},{"key":"1477_CR9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1752-1947-8-34","volume":"8","author":"S Nennstiel","year":"2014","unstructured":"Nennstiel S, Bajbouj M, Schmid RM, Becker V (2014) Prucalopride reduces the number of reflux episodes and improves subjective symptoms in gastroesophageal reflux disease: a case series. J Med Case Rep 8:34","journal-title":"J Med Case Rep"},{"key":"1477_CR10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1572-0241.2002.05396.x","volume":"97","author":"GE Boeckxstaens","year":"2002","unstructured":"Boeckxstaens GE, Bartelsman JFWM, Lauwers L, Tytgat GNJ (2002) Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol 97:194\u2013197","journal-title":"Am J Gastroenterol"},{"key":"1477_CR11","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1007\/s10620-010-1229-y","volume":"55","author":"CE Sloots","year":"2010","unstructured":"Sloots CE, Rykx A, Cools M, Kerstens R, De Pauw M (2010) Efficacy and safety of prucalopride in patients with chronic non cancer pain suffering from opioid-induced constipation. Dig Dis Sci 55:2912\u20132921","journal-title":"Dig Dis Sci"},{"key":"1477_CR12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/003655202317316060","volume":"37","author":"K Krogh","year":"2002","unstructured":"Krogh K, Jensen MB, Gandrup P et al (2002) Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol 37:431\u2013436","journal-title":"Scand J Gastroenterol"},{"key":"1477_CR13","first-page":"513","volume":"78","author":"O Dagtekin","year":"2012","unstructured":"Dagtekin O (2012) Prucalopride in a case of severe opioid induced constipation. Minerva Anestesiol 78:513\u2013514","journal-title":"Minerva Anestesiol"},{"key":"1477_CR14","first-page":"A256","volume":"11","author":"B D\u2019Hooghe","year":"1999","unstructured":"D\u2019Hooghe B, Guillaum D (1999) Treatment of constipation in multiple sclerosis patients: pilot study with the novel enterokinetic prucalopride. Neurogastroenterol Motil 11:A256","journal-title":"Neurogastroenterol Motil"},{"key":"1477_CR15","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/gut.45.5.713","volume":"45","author":"BY Winter De","year":"1999","unstructured":"De Winter BY, Boeckxstaens GE, De Man JG et al (1999) Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats. Gut 45:713\u2013718","journal-title":"Gut"},{"key":"1477_CR16","doi-asserted-by":"crossref","first-page":"A138","DOI":"10.1016\/S0016-5085(08)60640-X","volume":"134","author":"S Galandiuk","year":"2008","unstructured":"Galandiuk S, Beyens G, Ausma J (2008) Evaluation of the efficacy safety and tolerability of prucalopride (Resolor (R)) given subcutaneously in patients undergoing elective partial colectomies. Gastroenterology 134:A138","journal-title":"Gastroenterology"},{"key":"1477_CR17","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/apt.13557","volume":"43","author":"J Gong","year":"2016","unstructured":"Gong J, Xie Z, Zhang T et al (2016) Randomised clinical trial: prucalopride, a colonic pro-motility agent, reduces the duration of post-operative ileus after elective gastrointestinal surgery. Aliment Pharmacol Ther 43:778\u2013789","journal-title":"Aliment Pharmacol Ther"},{"key":"1477_CR18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/MCG.0000000000000145","volume":"49","author":"MC Giglio","year":"2014","unstructured":"Giglio MC, Luglio G, Tarquini R, Cerbone D, Bucci P, Bucci L (2014) Role of prucalopride in treatment of chronic constipation and recurrent functional obstruction in a patient with Steinert myotonic dystrophy. J Clin Gastroenterol 49:85\u201386","journal-title":"J Clin Gastroenterol"},{"key":"1477_CR19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2036.2011.04907.x","volume":"35","author":"AV Emmanuel","year":"2012","unstructured":"Emmanuel AV, Kamm MA, Roy AJ, Kerstens R, Vandeplassche L (2012) Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction\u2014a double-blind, placebo-controlled, crossover, multiple n\u00a0=\u00a01 study. Aliment Pharmacol Ther 35:48\u201355","journal-title":"Aliment Pharmacol Ther"},{"key":"1477_CR20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/gast.2001.21166","volume":"120","author":"EP Bouras","year":"2001","unstructured":"Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR (2001) Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 120:354\u2013360","journal-title":"Gastroenterology"},{"key":"1477_CR21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2036.2011.04947.x","volume":"35","author":"P Oustamanolakis","year":"2012","unstructured":"Oustamanolakis P, Tack J (2012) Prucalopride for chronic intestinal pseudo-obstruction. Aliment Pharmacol Ther 35:398\u2013399","journal-title":"Aliment Pharmacol Ther"},{"key":"1477_CR22","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1111\/j.1463-1318.2011.02929.x","volume":"14","author":"CJ Smart","year":"2012","unstructured":"Smart CJ, Ramesh AN (2012) The successful treatment of acute refractory pseudo-obstruction with prucalopride. Colorectal Dis 14:e508","journal-title":"Colorectal Dis"},{"key":"1477_CR23","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/bph.12397","volume":"170","author":"J Broad","year":"2013","unstructured":"Broad J, Kung VW, Boundouki G et al (2013) Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility. Br J Pharmacol 170:1253\u20131261","journal-title":"Br J Pharmacol"},{"key":"1477_CR24","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00036.2016","author":"F Bianco","year":"2016","unstructured":"Bianco F, Bonora E, Natarajan D et al (2016) Prucalopride exerts neuroprotection in human enteric neurons. Am J Physiol Gastrointest Liver Physiol. doi: 10.1152\/ajpgi.00036.2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"Suppl 2","key":"1477_CR25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2982.2007.00962.x","volume":"19","author":"MD Gershon","year":"2007","unstructured":"Gershon MD, Liu MT (2007) Serotonin and neuroprotection in functional bowel disorders. Neurogastroenterol Motil 19(Suppl 2):19\u201324","journal-title":"Neurogastroenterol Motil"},{"key":"1477_CR26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jneuroim.2006.06.012","volume":"179","author":"EM Zeinstra","year":"2006","unstructured":"Zeinstra EM, Wilczak N, Wilschut JC et al (2006) 5HT4 agonists inhibit interferon-\u03b3-induced MHC class II and B7 costimulatory molecules expression on cultured astrocytes. J Neuroimmunol 179:191\u2013195","journal-title":"J Neuroimmunol"},{"key":"1477_CR27","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.bjp.0707178","volume":"150","author":"M Cachard-Chastel","year":"2007","unstructured":"Cachard-Chastel M, Lezoualc\u2019h F, Dewachter I et al (2007) 5-HT4 receptor agonists increase sAPPa levels in the cortex and hippocampus of male C57BL\/6j mice. Br J Pharmacol 150:883\u2013892","journal-title":"Br J Pharmacol"},{"key":"1477_CR28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.bbr.2007.10.008","volume":"187","author":"M Cachard-Chastel","year":"2008","unstructured":"Cachard-Chastel M, Deverse S, Sicsic S et al (2008) Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl\/6j mice. Behav Brain Res 187:455\u2013461","journal-title":"Behav Brain Res"},{"key":"1477_CR29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/cns.12436","volume":"21","author":"S Navailles","year":"2015","unstructured":"Navailles S, Di Giovanni G, De Deurwaerd\u00e8re P (2015) The 5-HT4 agonist prucalopride stimulates L-DOPA-induced dopamine release in restricted brain regions of the hemiparkinsonian rat in vivo. CNS Neurosci Ther 21:745\u2013747","journal-title":"CNS Neurosci Ther"}],"container-title":["Techniques in Coloproctology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10151-016-1477-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10151-016-1477-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10151-016-1477-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T10:40:45Z","timestamp":1559126445000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10151-016-1477-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,12]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["1477"],"URL":"https:\/\/doi.org\/10.1007\/s10151-016-1477-8","relation":{},"ISSN":["1123-6337","1128-045X"],"issn-type":[{"value":"1123-6337","type":"print"},{"value":"1128-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,12]]}}}